A short term cost-effectiveness model for oral antidiabetic medicines in Europe

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 317-326

  Hood, Sheila C ^a   Annemans, Lieven ^b   Mölken, Maureen Rutten Van ^c   Lacey, Loretto ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b HEDM Research and Consulting   (Belgium)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUSTRY; EUROPE; PHARMACOECONOMICS; PRIORITY JOURNAL; SYMPTOMATOLOGY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; EUROPE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MODELS, ECONOMIC;

EID: 0031915234     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00006     Document Type: Article

References (29)

1. Alberti KGMM, Fries FA, Jervell J, et al. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an Update. Diabet Med 1994; 11: 899-909
2. Garg A. Treatment of dyslipidemia in patients with NIDDM. Diabetes Rev 1995; 3 (3): 433-45
3. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15 (6): 737-54
4. Clissold ST, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35: 214-43
5. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49 (5): 721-49
6. Pauker SG. Coronary artery surgery: the use of decision analysis. Ann Intern Med 1976; 85: 8-18
7. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co, 1980: 228-65
8. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analysis. JAMA 1995; 273: 712-20
9. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996; 124: 164-9
10. Schipper CK, Rutten FFH, Loffeld FJLF. Kosten en effectiviteit van diagnostiek en behandeling van patiënten met dyspepsie, bepaald met een computermodel. Ned Tijdschr Geneeskd 1993; 137: 1767-71
11. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-27
12. Zbrozek AS, Whalen E, Smith ME. Cost burden of newly-treated, non-insulin-dependent diabetes mellitus. Am J Managed Care 1997; 3 (3): S27-8
13. Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus: report of a joint working party of the British Diabetic Association, the Research Unit of the Royal College of Physicians and the Royal College of General Practitioners. J R Coll Physicians Lond 1993; 27 (3): 259-66
14. UKPDS Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8
15. Turner R, Cull C, Holman R. the UK Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomised, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124 (1 Pt 2): 136-45
16. Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. Pharmacoeconomics 1994; 5 (6): 505-12
17. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333 (9): 541-9
18. Ferner RE, Neil HA. Sulphonylureas and hypoglycaemia. BMJ 1988; 296: 104-9
19. Tessier D, Dawson K, Tetrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11: 974-80
20. Palmer KJ, Brogden RN. Gliclazide: an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46: 92-125
21. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1995; 331: 1188-93
22. Colwell JA. The feasibility of intensive insulin management in non-insulin dependent diabetes mellitus. Ann Intern Med 1996; 124: 131-5
23. Johnson JL, Wolf SL, Kubadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156 (3): 259-64
24. Drummond M, Rutten F, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 1993; 4: 173-86
25. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992; 49: 1741-7
26. Langley PC. Outcomes research and modelling therapeutic interventions for economic evaluation. Clin Ther 1994; 16: 538-52
27. Brown JB, Glauber HS, Nichols GA, et al. Costs and anti-hyperglycaemic drug use over 8 years among HMO members newly diagnosed with type 2 diabetes. Am J Managed Care 1997; 3 (3): S45-6
28. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15 (6): 755-67
29. Henry RR, Genuth S. Forum one: current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124 (1 Pt 2): 175-7